Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Nano-X Imaging Ltd. is a medical imaging technology company focused on developing and commercializing innovative X-ray imaging systems designed to improve accessibility and affordability of diagnostic imaging. The company operates within the medical devices and healthcare imaging industries, targeting global radiology markets that are underserved by conventional imaging infrastructure. Its core value proposition centers on reducing the cost, size, and complexity of X-ray systems through proprietary digital technology.
The company’s primary revenue drivers are expected to come from sales and deployment of its digital X-ray imaging systems and related services, including imaging-as-a-service models. Nano-X positions itself as a disruptor in traditional radiology by emphasizing lower capital expenditure requirements and cloud-enabled image processing. The company was founded in 2012 and went public in 2020, evolving from a technology development-stage enterprise into a commercial-stage company following regulatory clearances for its imaging systems in multiple jurisdictions.
Business Operations
Nano-X Imaging operates primarily through its medical imaging business, which focuses on the development, manufacturing, and commercialization of its proprietary digital X-ray systems, most notably the Nano-X.ARC. The company generates revenue through system sales, usage-based fees, and service contracts, with an emphasis on recurring revenue models tied to imaging volume. Operations include system manufacturing, software development, cloud-based image processing, and regulatory compliance activities.
The company maintains domestic and international operations, including research and development centers and manufacturing partnerships. It controls proprietary cold cathode X-ray source technology and cloud-based software platforms designed to support remote diagnostics and AI-enabled image analysis. Nano-X also owns USARAD Holdings Inc., a teleradiology services company, which supports its strategy to integrate hardware, software, and diagnostic services into a unified ecosystem.
Strategic Position & Investments
Nano-X’s strategic direction emphasizes global deployment of affordable imaging systems, particularly in emerging and underserved markets where access to radiology services is limited. Growth initiatives include expanding regulatory approvals, increasing system installations, and scaling its imaging-as-a-service model. The company has invested significantly in research and development to advance its digital X-ray source technology and software capabilities.
A key strategic investment was the acquisition of USARAD Holdings Inc., which provides teleradiology services and strengthens Nano-X’s end-to-end imaging solution. The company is also involved in emerging technologies such as AI-assisted diagnostics and cloud-based medical imaging platforms, although commercialization of these capabilities remains ongoing. Data inconclusive based on available public sources regarding the pace and scale of adoption of certain emerging technologies.
Geographic Footprint
Nano-X Imaging is headquartered in Israel, with additional corporate offices and operational presence in the United States. The company’s market focus spans North America, Europe, Asia, Latin America, and parts of Africa, reflecting its strategy to address global disparities in medical imaging access. Regulatory clearances have been pursued across multiple regions to enable broader commercialization.
Internationally, Nano-X’s influence is primarily through distribution partnerships, pilot installations, and service agreements rather than wholly owned manufacturing facilities. Its geographic footprint continues to evolve as regulatory approvals, customer adoption, and deployment milestones progress. Data inconclusive based on available public sources regarding full commercial scale in all targeted regions.
Leadership & Governance
Nano-X Imaging was founded by Ran Poliakine, who has played a central role in shaping the company’s technological vision and long-term strategy. The leadership team emphasizes innovation, cost reduction in healthcare delivery, and expanding global access to diagnostic imaging through technology-driven solutions.
Key executives include:
- Ran Poliakine – Founder and Executive Chairman
- Erez Meltzer – Chief Executive Officer
- Ran Daniel – Chief Financial Officer
- Adi Cohen – Chief Technology Officer
- Hila Goldman-Aslan – Chief Regulatory and Clinical Affairs Officer
The company’s governance structure reflects its status as a publicly traded company, with oversight aligned to regulatory requirements and a strategic focus on long-term value creation through technology commercialization and global market expansion.